Early vascular aging in hypertension
AbstractWith increasing age, the cardiovascular risk increases, as does frailty, with negative health consequences such as coronary disease, stroke, and vascular dementia. However, this aging process seems to take a more rapid course in some individuals, as reflected in the Early Vascular Aging (EVA) syndrome that over the recent 10 years has attracted increased attention. The core of the EVA syndrome is arterial stiffness in the media layer of large elastic arteries, a process that can be measured by pulse wave velocity, for example, along the aorta. Hypertension is a well-known cardiovascular risk factor in its own right, but also linked to the EVA process. However, several studies have shown that non-hemodynamic factors also contribute to arterial stiffness and EVA, such as impaired glucose metabolism, chronic inflammation, and oxidative stress. New perspectives have been introduced for linking early life programming affecting new-born babies and birth weight, with a later risk of hypertension, arterial stiffness and EVA. New drugs are being developed to treat EVA when lifestyle intervention and conventional risk factor controlling drugs are not enough. Finally, the opposite phenotype of EVA is Healthy Vascular Aging (HVA) or even Super Normal Vascular Aging (SUPERNOVA). If protective mechanisms can be found and mapped in these fortunate subjects with a slower than expected aging process, there could exist a potential to find new drug targets for preventive therapy.
Keywords:aging; artery; glucose; hypertension; inflammation; oxidative stress
References
1. Olsen M.H., Angell S.Y., Asma S., Boutouyrie P., Burger D., Chirinos J.A., et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016; 388: 2665–712. DOI: https://doi.org/10.1016/S0140-6736(16)31134-5
2. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120: 1640–5. DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.192644
3. Kahn R., Buse J., Ferrannini E., Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2005; 48: 1684–99. DOI: https://doi.org/10.1007/s00125-005-1876-2
4. Nilsson P.M. Early vascular aging (EVA): consequences and prevention. Vasc Health Risk Manag. 2008; 4: 547–52. DOI: https://doi.org/10.2147/VHRM.S1094
5. Nilsson P.M., Lurbe E., Laurent S. The early life origins of vascular ageing and cardiovascular risk: the EVA syndrome. J Hypertens. 2008; 26: 1049–57. DOI: https://doi.org/10.1097/HJH.0b013e3282f82c3e
6. Vlachopoulos C., Xaplanteris P., Aboyans V., Brodmann M., Cífková R., Cosentino F., et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis. 2015; 241: 507–32. DOI: https://doi.org/10.1016/j.atherosclerosis.2015.05.007
7. Salvi P., Scalise F., Rovina M., Moretti F., Salvi L., Grillo A., et al. Noninvasive estimation of aortic stiffness through different approaches. Hypertension. 2019; 74: 117–29. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.119.12853
8. Nilsson P.M., Boutouyrie P., Laurent S. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension. 2009; 54: 3–10. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.109.129114
9. Gottsäter M., Östling G., Persson M., Engström G., Melander O., Nilsson P.M. Non-hemodynamic predictors of arterial stiffness after 17 years of follow-up: the Malmö Diet and Cancer study. J Hypertens. 2015; 33: 957–65. DOI: https://doi.org/10.1097/HJH.0000000000000520
10. Guzik T.J., Touyz R.M. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension. 2017; 70: 660–7. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.117.07802
11. Kaess B.M., Rong J., Larson M.G., Hamburg N.M., Vita J.A., Levy D., et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA. 2012; 308: 875–81. DOI: https://doi.org/10.1001/2012.jama.10503
12. AlGhatrif M., Strait J.B., Morrell C.H., Canepa M., Wright J., Elango P., et al. Longitudinal trajectories of arterial stiffness and the role of blood pressure: the Baltimore Longitudinal Study of Aging. Hypertension. 2013; 62: 934–41. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.113.01445
13. Muhammad I.F., Borné Y., Östling G., Kennbäck C., Gottsäter M., Persson M., et al. Arterial stiffness and incidence of diabetes: a population-based cohort study. Diabetes Care. 2017; 40: 1739–45. DOI: https://doi.org/10.2337/dc17-1071
14. Gottsäter M., Hindy G., Orho-Melander M., Nilsson P.M., Melander O. A genetic risk score for fasting plasma glucose is independently associated with arterial stiffness: a Mendelian randomization study. J Hypertens. 2018; 36: 809–14. DOI: https://doi.org/10.1097/HJH.0000000000001646
15. Cunha P.G., Boutouyrie P., Nilsson P.M., Laurent S. Early vascular ageing (EVA): definitions and clinical applicability. Curr Hypertens Rev. 2017; 13: 8–15. DOI: https://doi.org/10.2174/1573402113666170413094319
16. Reference Values for Arterial Stiffness’ Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: “establishing normal and reference values”. Eur Heart J. 2010; 31: 2338–50. DOI: https://doi.org/10.1093/eurheartj/ehq165
17. Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 55: 1318–27. DOI: https://doi.org/10.1016/j.jacc.2009.10.061
18. Ben-Shlomo Y., Spears M., Boustred C., May M., Anderson S.G., Benjamin E.J., et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014; 63: 636–46. DOI: https://doi.org/10.1016/j.jacc.2013.09.063
19. Zhong Q., Hu M.J., Cui Y.J., Liang L., Zhou M.M., Yang Y.W., et al. Carotid-femoral pulse wave velocity in the prediction of cardiovascular events and mortality: an updated systematic review and meta-analysis. Angiology. 2018; 69: 617–29. DOI: https://doi.org/10.1177/0003319717742544
20. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018; 36: 1953–2041. DOI: https://doi.org/10.1097/HJH.0000000000001940
21. Zanoli L., Rastelli S., Granata A., Inserra G., Empana J.P., Boutouyrie P., et al. Arterial stiffness in inflammatory bowel disease: a systematic review and meta-analysis. J Hypertens. 2016; 34: 822–9. DOI: https://doi.org/10.1097/HJH.0000000000000867
22. Lacolley P., Regnault V., Segers P., Laurent S. Vascular smooth muscle cells and arterial stiffening: relevance in development, aging, and disease. Physiol Rev. 2017; 97: 1555–617. DOI: https://doi.org/10.1152/physrev.00003.2017
23. Visentin S., Grumolato F., Nardelli G.B., Di Camillo B., Grisan E., Cosmi E. Early origins of adult disease: low birth weight and vascular remodeling. Atherosclerosis. 2014; 237: 391–9. DOI: https://doi.org/10.1016/j.atherosclerosis.2014. 09.027
24. Sperling J., Nilsson P.M. Does early life programming influence arterial stiffness and central hemodynamics in adulthood? J Hypertens. 2020; 38: 481–8. DOI: https://doi.org/10.1097/HJH.0000000000002292
25. Stock K., Schmid A., Griesmaier E., Gande N., Hochmayr C., Knoflach M., et al. The impact of being born preterm or small for gestational age on early vascular aging in adolescents. J Pediatr. 2018; 201: 49–54. DOI: https://doi.org/10.1016/j.jpeds.2018.05.056
26. Warrington N.M., Beaumont R.N., Horikoshi M., Day F.R., Helgeland O., Laurin C., et al. Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors. Nat Genet. 2019; 51: 804–14. DOI: https://doi.org/10.1038/s41588-019-0403-1
27. Symonds M.E., Stephenson T., Budge H. Early determinants of cardiovascular disease: the role of early diet in later blood pressure control. Am J Clin Nutr. 2009; 89: 1518S-22S. DOI: https://doi.org/10.3945/ajcn.2009.27113F
28. Henskens L.H., Kroon A.A., van Oostenbrugge R.J., Gronenschild E.H., Fuss-Lejeune M.M., Hofman P.A., et al. Increased aortic pulse wave velocity is associated with silent cerebral small-vessel disease in hypertensive patients. Hypertension. 2008; 52: 1120–6. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.108.119024
29. Savoia C., Battistoni A., Calvez V., Cesario V., Montefusco G., Filippini A. Microvascular alterations in hypertension and vascular aging. Curr Hypertens Rev. 2017; 13: 16–23. DOI: https://doi.org/10.2174/1573402113666170505115010
30. Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Goldberger Z.D., Hahn E.J., et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140: e563–95. DOI: https://doi.org/10.1161/CIR.0000000000000677
31. Ong K.T., Delerme S., Pannier B., Safar M.E., Benetos A., Laurent S., et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens. 2011; 29: 1034–42. DOI: https://doi.org/10.1097/HJH.0b013e328346a583
32. Vlachopoulos C., Terentes-Printzios D., Laurent S., Nilsson P.M., Protogerou A.D., Aznaouridis K., et al. Association of estimated pulse wave velocity with survival: a secondary analysis of SPRINT. JAMA Netw Open. 2019; 2: e1912831. DOI: https://doi.org/10.1001/jamanetworkopen.2019.12831
33. Laurent S., Schlaich M., Esler M. New drugs, procedures, and devices for hypertension. Lancet. 2012; 380: 591–600. DOI: https://doi.org/10.1016/S0140-6736(12)60825-3
34. Mancia G., Cannon C.P., Tikkanen I., Zeller C., Ley L., Woerle H.J., et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension. 2016; 68: 1355–64. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.116.07703
35. Chilton R., Tikkanen I., Cannon C.P., Crowe S., Woerle H.J., Broedl U.C., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015; 17: 1180–93. DOI: https://doi.org/10.1111/dom.12572
36. Niiranen T.J., Lyass A., Larson M.G., Hamburg N.M., Benjamin E.J., Mitchell G.F., et al. Prevalence, correlates, and prognosis of healthy vascular aging in a western community-dwelling cohort: the Framingham Heart Study. Hypertension. 2017; 70: 267–74. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.117.09026
37. Nilsson P.M., Laurent S., Cunha P.G., Olsen M.H., Rietzschel E., Franco O.H., et al. Characteristics of healthy vascular ageing in pooled population-based cohort studies: the global Metabolic syndrome and Artery Research Consortium. J Hypertens. 2018; 36: 2340–9. DOI: https://doi.org/10.1097/HJH.0000000000001824
38. Ji H., Teliewubai J., Lu Y., Xiong J., Yu S., Chi C., et al. Vascular aging and preclinical target organ damage in community-dwelling elderly: the Northern Shanghai Study. J Hypertens. 2018; 36: 1391–8. DOI: https://doi.org/10.1097/HJH.0000000000001692
39. Laurent S., Boutouyrie P., Cunha P.G., Lacolley P., Nilsson P.M. Concept of extremes in vascular aging. Hypertension. 2019; 74: 218–28. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.119.12655
40. Bain S.C., Gill G.V., Dyer P.H., Jones A.F., Murphy M., Jones K.E., et al. Characteristics of Type 1 diabetes of over 50 year’s duration (the Golden Years Cohort). Diabet Med. 2003; 20: 808–11. DOI: https://doi.org/10.1046/j.1464-5491.2003.01029.x
41. Sun J.K., Keenan H.A., Cavallerano J.D., Asztalos B.F., Schaefer E.J., Sell D.R., et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-year medalist study. Diabetes Care. 2011; 34: 968–74. DOI: https://doi.org/10.2337/dc10-1675
42. Adamsson Eryd S., Svensson A.M., Franzén S., Eliasson B., Nilsson P.M., Gudbjörnsdottir S. Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up. Diabet Med. 2017; 34: 411–8. DOI: https://doi.org/10.1111/dme.13266
43. Nilsson P.M. Hemodynamic aging as the consequence of structural changes associated with early vascular aging (EVA). Aging Dis. 2014; 5: 109–13. DOI: https://doi.org/10.14336/AD.2014.0500109
44. Tremmel M., Lyssenko V., Zöller B., Engström G., Magnusson M., Melander O., et al. Characteristics and prognosis of healthy severe obesity (HSO) subjects – The Malmo Preventive Project. Obes Med. 2018; 11: 6–12. DOI: https://doi.org/10.1016/j.obmed.2018.06.005
45. Korduner J., Bachus E., Jujic A., Magnusson M., Nilsson P.M. Metabolically Healthy Obesity (MHO) in the Malmö Diet Cancer Study – epidemiology and prospective risks. Obes Res Clin Pract. 2019; 13: 548–54. DOI: https://doi.org/10.1093/eurheartj/ehz748.0079
46. Nilsson P.M., Boutouyrie P., Cunha P., Kotsis V., Narkiewicz K., Parati G., et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. 2013; 31: 1517–26. DOI: https://doi.org/10.1097/HJH.0b013e328361e4bd
47. Danninger K., Hafez A., Binder R.K., Aichberger M., Hametner B., Wassertheurer S., et al. High prevalence of hypertension and early vascular aging: a screening program in pharmacies in Upper Austria. J Hum Hypertens. 2020; 34: 326–34. DOI: https://doi.org/10.1038/s41371-019-0222-y